Drug Profile
Research programme: Alzheimer's disease diagnostics - Axonyx/University of Melbourne
Latest Information Update: 24 Jan 2003
Price :
$50
*
At a glance
- Originator University of Melbourne
- Class Cholinesterases; Diagnostic agents
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Alzheimer's disease
Most Recent Events
- 24 Jan 2003 Discontinued - Preclinical for Alzheimer's disease (diagnosis) in Australia (unspecified route)
- 17 Jan 2003 Axonyx has decided to out-license or cancel its diagnostic programme for Alzheimer's disease
- 17 May 2000 Preclinical development for Alzheimer's disease (diagnosis) in Australia (unspecified route)